{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"}],"units":"Participants"}],"description":"Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.","groups":[{"description":"1/Phase I:\n\nDrug: Fludarabine Days -5 to Day -1: Fludarabine 25 mg/m\\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.\n\nOther Names: •Fludara\n\nBiological/Vaccine: Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)\n\nDay 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.\n\nDrug: Cyclophosphamide Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.\n\nOther Names: •Cytoxan\n\nDrug: Aldesleukin Aldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).\n\nOther Names: •Proleukin","id":"OG000","title":"Arm A01 Anti-mesothelin CAR PBL 1x10^6 + IL-2"},{"description":"1/Phase I:\n\nDrug: Fludarabine Days -5 to Day -1: Fludarabine 25 mg/m\\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.\n\nOther Names: •Fludara\n\nBiological/Vaccine: Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)\n\nDay 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.\n\nDrug: Cyclophosphamide Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.\n\nOther Names: •Cytoxan\n\nDrug: Aldesleukin Aldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).\n\nOther Names: •Proleukin","id":"OG001","title":"Arm A02 Anti-mesothelin CAR PBL 3x10^6 + IL-2"},{"description":"1/Phase I:\n\nDrug: Fludarabine Days -5 to Day -1: Fludarabine 25 mg/m\\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.\n\nOther Names: •Fludara\n\nBiological/Vaccine: Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)\n\nDay 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.\n\nDrug: Cyclophosphamide Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.\n\nOther Names: •Cytoxan\n\nDrug: Aldesleukin Aldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).\n\nOther Names: •Proleukin","id":"OG002","title":"Arm A03 Anti-mesothelin CAR PBL 1x10^7 + IL-2"},{"description":"1/Phase I:\n\nDrug: Fludarabine Days -5 to Day -1: Fludarabine 25 mg/m\\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.\n\nOther Names: •Fludara\n\nBiological/Vaccine: Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)\n\nDay 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.\n\nDrug: Cyclophosphamide Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.\n\nOther Names: •Cytoxan\n\nDrug: Aldesleukin Aldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).\n\nOther Names: •Proleukin","id":"OG003","title":"Arm A04 Anti-mesothelin CAR PBL 3x10^7 + IL-2"},{"description":"1/Phase I:\n\nDrug: Fludarabine Days -5 to Day -1: Fludarabine 25 mg/m\\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.\n\nOther Names: •Fludara\n\nBiological/Vaccine: Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)\n\nDay 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.\n\nDrug: Cyclophosphamide Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.\n\nOther Names: •Cytoxan\n\nDrug: Aldesleukin Aldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).\n\nOther Names: •Proleukin","id":"OG004","title":"Arm A05 Anti-mesothelin CAR PBL 1x10^8 + IL-2"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Date treatment consent signed to date off study, approximately 6 months and 17 days for Group A01, 16 months and 13 days for Group A02, 13 months and 3 days for Group A03, 10 months and 16 days for Group A04, and 11 months and 26 days for Group A05.","title":"Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)","type":"PRIMARY","unitOfMeasure":"Participants"}